Navigation Links
Plicera in Medical Technology

Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease

Phase 2 Clinical Trials Initiated CRANBURY, N.J., March 21, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present p...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

...olly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. Under the terms of the collaboration Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay ti...

Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent

...trengthens our protection in the United States for plicera in Gaucher and is one example of our ongoing effor...armacological chaperone technology platform." plicera is currently being studied in an ongoing Phase 2 s...e third quarter of 2009. Amicus is developing plicera as part of a strategic collaboration with Shire Hu...

Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. Forward-Looking Statements This press release contain...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

...he dose and regimen for the Phase 3 studies. plicera (TM) (isofagomine tartrate) for the treatment of Gaucher Disease A Phase 2 clinical trial of plicera in Gaucher patients is ongoing. This 6 month study...er Shire HGT to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... for the ongoing 6-month Phase 2 clinical trial of plicera in patients naive to ERT to include modified doses... The Company has modified its development plan for plicera to include a study of the pharmacokinetics of plicera in Gaucher patients. In addition, the company no l...

Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease

...Nashville, TN. The data demonstrate the ability of plicera to increase levels of the target enzyme in cells d...l data from both studies will also be presented. plicera is designed to selectively bind to and stabilize G... The following is a summary of the preclinical plicera data being presented at ACMG. - In vitro ex...
Plicera in Biological Technology

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...rldwide will participate in this trial. plicera (TM) (afegostat tartrate) for the treatment of ...inical trial of the Company's investigational drug plicera is ongoing. This 6-month study is designed to eval..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Publication of Shire plc's Annual Report 2008

...IGAL and AT2220, in markets outside the US. plicera (HGT-3410 for the treatment of Gaucher disease) plicera is an orally-administered, small molecule pharmaco...port the previously reported interim findings that plicera was generally safe and well tolerated at all doses...

Amicus Therapeutics Announces Change to Board of Directors

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...

Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results

... be available in the first quarter of 2009. plicera (TM) (isofagomine tartrate) for the treatment o...on executing its ongoing Phase 2 clinical trial of plicera in Gaucher disease. This 6-month study is designed..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD -G ...

Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors

...medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...

Amicus Therapeutics Announces Third Quarter 2008 Financial Results

...ucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of plicera in patients naive to ERT is ongoing and Amicus expects the results of this ...harmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration, valued at up to $440 million including a...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...s Phase 2 trial support the previously reported interim findings that plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. Shire has rights to plicera in markets outside the US. HGT-3510 - Pompe disease - In June 2008 Ami...

Amicus Therapeutics Announces First Quarter 2008 Financial Results

...macological chaperone Plicera. Results showed that plicera was generally safe and well tolerated at all doses...protocol for the 6-month Phase 2 clinical trial of plicera patients naive to ERT to include modified doses an...compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration valued at up to ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...ine) METAZYM(TM) (arylsulfatase-A) MEZAVANT(R) (mesalazine) PENTASA (mesalamine) (trademark of Ferring) plicera (isofagomine tartrate) (trademark of Amicus) RAZADYNE (galantamine) (trademark of Johnson & Johnson ...
Other Tags
(Date:9/16/2014)... abnormalities in the adrenergic and noradrenergic systems, both ... play a role in the development of post-traumatic ... no genetic evidence of this connection. A collaborative ... Mailman School of Public Health and the University ... gene and childhood adversity. For individuals with two ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Beginning October 1st ... a new service offering for its clients who book a ... the volume of business they buy. Most recurring visit ... during the work week, but others include clients whose unique ... pet sitter on a daily basis. The newly ...
(Date:9/16/2014)... 16, 2014 The Pain Center ... by Ranking Arizona magazine, has selected Analance ™, ... enterprise. , With TPC seeing hundreds of thousands ... repository that was managed through “home grown” systems trying ... and clinical leadership teams. “Our current tools were ...
(Date:9/16/2014)... 2014 Founded by former Miami Beach ... a political organization fighting to legalize medical marijuana in ... The After Party recently commissioned a shot-for-shot parody video ... from the movie “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called ... the musical parody faithfully recreates the carnival scene made ...
(Date:9/16/2014)... 16, 2014 Synergy Research Group has ... gives the best detail and analysis of the state ... a variety of sources, including Ministry of Health in ... will give readers actionable intelligence on clinical trials in ... relied on by the local and international life science ...
Breaking Medicine News(10 mins):Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Synergy Research Group Debuts Ukraine Orange Paper 2
(Date:9/16/2014)... BEACH GARDENS, Fla. , Sept. 16, 2014 ... of biometric identity management solutions, announced today the ... solution designed to authenticate the identity of an ... The Android-based Verifier Sentry rapidly reads credential ... credential holder,s ID by matching the biometric to ...
(Date:9/15/2014)... Human skin and gut microbes influence processes from digestion ... are the most biodiverse terrestrial ecosystems on the planet, ... trees in the tropics. Smithsonian scientists and colleagues working ... samples from a single tree were home to more ... from 57 tree species contained more than 7,000 different ...
(Date:9/15/2014)... mechanical solution to avoid chromosome sorting errors, researchers ... Express. , This natural safeguard prevents ... infertility, miscarriage, or congenital conditions. , "Mistakes ... what exactly goes wrong is often not understood," ... for Cell Biology at the University of Edinburgh ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Smithsonian scientists discover tropical tree microbiome in Panama 2Cells simply avoid chromosome confusion 2Cells simply avoid chromosome confusion 3
Other Contents